Memento Medicines
Latest round
- Series A
Last raised
- Jun 2026
Total raised
- $38M
Investors
- 5
About Memento Medicines
Founded in 2026 and based in Boston, MA, the company's CEO is Naveen Daryani. Memento Medicines, Inc. that provided antibody therapies for retinal diseases. In June 2026, Memento Medicines, Inc., Ltd., Ltd.. MMT-205 is designed to simultaneously activate the Tie2 receptor and inhibit VEGF, two clinically validated pathways involved in retinal and vascular diseases. The therapy is intended to improve upon existing anti-VEGF treatments by enhancing retinal vascular stability and potentially delivering improved efficacy and durability.
Who invested in Memento Medicines
5 investors across 1 round
See all investors in Memento Medicines
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Jun 3, 2026
Amount
$38M
Investors
Questions about Memento Medicines
Who invested in Memento Medicines?
Memento Medicines has 5 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Memento Medicines raised?
Memento Medicines has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Memento Medicines last raise money?
Memento Medicines's most recent round on record is a Series A, in Jun 2026.
What does Memento Medicines do?
Founded in 2026 and based in Boston, MA, the company's CEO is Naveen Daryani.
Where is Memento Medicines headquartered?
Memento Medicines is headquartered in Boston, US.
Which VCs invest in companies like Memento Medicines?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Memento Medicines's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Memento Medicines? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.